Getinge Bundle
Who Really Owns Getinge?
Understanding the ownership structure of a global medical technology leader like the Getinge company is vital for investors and industry watchers alike. From its humble beginnings in Sweden to its current status as a healthcare powerhouse, Getinge's ownership has undergone significant transformations. This journey has profoundly impacted its strategic direction and market performance.
This exploration of Getinge ownership dives into the key players shaping its destiny. We'll examine the evolution of Getinge SWOT Analysis and its impact on the company's trajectory, from its founders and early backers to its current major shareholders, including institutional investors and public shareholders. Discover how these shifts have influenced Getinge's growth and its position in the competitive landscape of the healthcare industry, including its recent financial performance and future outlook.
Who Founded Getinge?
The story of Getinge, a prominent player in the medical technology field, began in 1904. Founded by Olander Larsson in the Swedish village of Getinge, the company initially focused on agricultural machinery before evolving significantly over time. Understanding the evolution of Getinge ownership is key to grasping its current structure and strategic direction.
The company's transformation from agricultural equipment to medical technology marked a critical shift. This transition, starting in 1932 with the production of sterilizers, set the stage for Getinge's current focus on healthcare solutions. The evolution of Getinge's history is a testament to its adaptability and strategic foresight.
The initial phase of Getinge company involved manufacturing and selling agricultural machinery. The company's Articles of Association, dated March 10, 1904, provides a clear picture of its early business activities. This initial foundation was crucial, laying the groundwork for its future endeavors.
Early Days
Olander Larsson founded Getinge in 1904 in Sweden. The company started as Getinge Nya Mekaniska Verkstad AB, focusing on agricultural machinery.
Transition to Medical Technology
In 1932, Getinge shifted its focus to medical technology. The company began producing sterilizers for hospitals and laboratories, marking a significant change in its business direction.
Electrolux Acquisition
Electrolux acquired Getinge in September 1964. This acquisition integrated Getinge into a larger multinational appliance group for 25 years.
Rune Andersson and Carl Bennet
Rune Andersson and Carl Bennet acquired Getinge from Electrolux in 1989. This marked a new phase in the company's ownership and strategic direction.
Carl Bennet's Ownership
Carl Bennet AB became the sole majority owner after acquiring Rune Andersson's share. This solidified Carl Bennet's long-term commitment to Getinge.
Current Status
Today, understanding the Getinge company ownership structure is crucial for investors and stakeholders. The company's history reflects its ability to adapt and grow in the healthcare sector.
Key Ownership Timeline
The ownership of Getinge has seen several significant changes over the years, each shaping the company's strategic direction and market position. From its early days as a manufacturer of agricultural machinery to its present focus on medical technology, the evolution of its ownership structure is a key factor in understanding its current operations. To better understand the Getinge AB market, consider exploring the Target Market of Getinge.
- 1904: Founded by Olander Larsson as Getinge Nya Mekaniska Verkstad AB.
- 1932: Transitioned into medical technology, producing sterilizers.
- 1964: Acquired by Electrolux.
- 1989: Acquired by Rune Andersson and Carl Bennet.
- Late 1990s: Carl Bennet AB becomes the sole majority owner.
Getinge SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Getinge’s Ownership Changed Over Time?
The evolution of Getinge's ownership has been marked by significant shifts since its inception. Initially acquired by Rune Andersson and Carl Bennet in 1989, the company transitioned to the Stockholm stock exchange in 1993. This move was a pivotal moment, setting the stage for further developments in its ownership structure and strategic direction. The inclusion in the OMXS30 Index since July 2009 further solidified its position in the market.
The ownership structure of the Getinge company has seen the influence of key stakeholders. The listing on the stock exchange in 1993 was a major step. The company's trajectory has been significantly shaped by these changes, including major acquisitions like Arjo in 1995 and Maquet in 2000, which formed the foundation for its core business segments.
| Shareholder | Shares Held (as of late 2024/early 2025) | Percentage of Shares |
|---|---|---|
| Carl Bennet AB | 36,918,434 (as of December 30, 2024) | 13.55% |
| Carl Bennet (Individual) | 55,020,169 (as of December 31, 2024) | 20.2% |
| Fjärde AP-fonden | 21,007,390 | 8.266% |
| AMF Fonder AB | 14,141,041 (as of February 20, 2025) | 5.564% |
| Carnegie Fonder AB | 13,695,886 (as of March 4, 2025) | 5.547% |
| Swedbank Robur Fonder AB | 16,528,943 (as of June 29, 2024) | 3.8% |
| The Vanguard Group, Inc. (as of December 30, 2023) | 8,334,371 | 3.06% |
| BlackRock, Inc. (as of December 30, 2023) | 7,664,252 (as of 2024 Annual Report: 8,818,388) | 2.81% (as of 2024 Annual Report: 3.24%) |
| Handelsbanken Asset Management (as of December 30, 2023) | 8,018,780 (as of 2024 Annual Report: 7,618,677) | 2.94% (as of 2024 Annual Report: 2.80%) |
| Norges Bank Investment Management (as of December 30, 2023) | 5,534,872 | 2.03% |
As of late 2024 and early 2025, the ownership structure of Getinge AB reveals a significant presence of institutional investors, holding approximately 40.9% of the shares. Individual insiders hold about 20.4%, while the general public holds 25.1%. Private companies own 13.6% of the shares. Carl Bennet AB remains a key player, holding 13.55% of the shares as of December 30, 2024, and Carl Bennet individually holds 20.2% as of December 31, 2024. This concentrated ownership provides stability and supports long-term value creation. Key institutional investors include Fjärde AP-fonden, AMF Fonder AB, and Carnegie Fonder AB. The data shows that over half of Getinge AB's outstanding shares are owned by external corporations, highlighting the company's integration into the broader financial market.
Key Takeaways on Getinge Ownership
The ownership of Getinge company is characterized by a mix of institutional and individual shareholders.
- Carl Bennet and Carl Bennet AB are major shareholders, ensuring stability.
- Institutional investors like Fjärde AP-fonden and AMF Fonder AB hold significant stakes.
- The ownership structure has evolved since the company's listing on the stock exchange.
- These changes have influenced Getinge's strategic decisions and acquisitions.
Getinge PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Getinge’s Board?
The corporate governance of the Getinge company adheres to Swedish law, the rules of Nasdaq Stockholm, and the Swedish Corporate Governance Code. The Board of Directors includes members representing major shareholders and independent members. Johan Malmquist is the Chairman of the Board. Carl Bennet, a major shareholder, serves as Vice Chairman and has been on the board since 1989. Dan Frohm is also a board member, though not considered independent relative to the company's major shareholders. The Nomination Committee, preparing for the 2025 Annual General Meeting (AGM), includes representatives from key owners such as Carl Bennet AB (Carl Bennet), Fourth Swedish National Pension Fund (Jannis Kitsakis), AMF Pension & Fonder (Dick Bergquist), Carnegie Fonder (Simon Blecher), and Swedbank Robur (Marianne Nilsson). The AGM is scheduled for April 22, 2025, in Halmstad, Sweden.
Ulrika Dellby has been proposed as a new Board member for the AGM on April 22, 2025, with re-election of all current Board members also proposed. This structure reflects the company's commitment to a balance of shareholder representation and independent oversight, ensuring that the interests of all stakeholders are considered in strategic decisions.
| Board Member | Role | Notes |
|---|---|---|
| Johan Malmquist | Chairman | |
| Carl Bennet | Vice Chairman | Major Shareholder |
| Dan Frohm | Board Member | Not considered independent |
| Ulrika Dellby | Proposed Board Member | For the 2025 AGM |
The voting structure at Getinge involves different share classes. Series A shares provide ten votes per share, whereas Series B and Series C shares each have one vote. This dual-class share structure gives Carl Bennet AB, the largest shareholder, significant control, holding over 50% of the votes. Shareholders can vote in person or by postal voting at the Annual General Meeting. The Board of Directors has the authority to decide on share repurchases to manage the capital structure and increase shareholder value. For more insights into how the company approaches its market, consider reading about the Marketing Strategy of Getinge.
Key Takeaways on Getinge Ownership
The ownership of the Getinge company is significantly influenced by its dual-class share structure, giving major shareholders considerable voting power.
- Carl Bennet AB holds a controlling stake.
- The Board of Directors includes representatives from major shareholders and independent members.
- Shareholders can exercise their voting rights at the Annual General Meeting.
- The 2025 AGM is scheduled for April 22, 2025.
Getinge Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Getinge’s Ownership Landscape?
Over the past few years, the focus of the Getinge company has been on strategic growth and enhancing operational efficiency. This has had a direct impact on its ownership profile. The company showcased strong financial results in 2024, with record sales and improved margins, which is a positive signal for investors. This performance can attract and retain institutional investors, influencing the Getinge ownership structure.
Institutional ownership remains a key aspect of Getinge AB (publ)'s shareholder base. As of June 10, 2024, the company had 176 institutional owners holding a total of 16,970,398 shares. Major institutional holders include The Vanguard Group, Inc., BlackRock, Inc., Swedbank Robur Fonder AB, and Carnegie Fonder AB, with holdings reported through early 2025. The company's 2024 Annual Report highlights a stable shareholder base with a long-term perspective. For deeper insights, you can explore the Growth Strategy of Getinge.
| Metric | Value | Year |
|---|---|---|
| Institutional Owners | 176 | June 10, 2024 |
| Total Shares Held by Institutions | 16,970,398 | June 10, 2024 |
| Anticipated Organic Sales Growth | 2-5% | 2025 (Full Year) |
Recent developments, such as the acquisition of Paragonix Technologies, Inc. in Q3 2024, have expanded Getinge's product portfolio. The Nomination Committee for the 2025 Annual General Meeting saw updates due to changes in the ownership structure, leading to new appointments. Furthermore, the company has decided to phase out the Surgical Perfusion product category to strengthen long-term growth, reallocating resources to areas like ECLS and Transplant Care. The company anticipates organic sales growth of 2-5% for the full year 2025. These strategic shifts and financial results are expected to continue shaping the Who owns Getinge profile as investors respond to its growth prospects and operational changes.
Getinge's Financial Performance
Getinge reported record sales in 2024, which is a positive indicator. Strong order intake and increased sales contributed to improved margins. This financial success can attract and retain institutional investors.
Ownership Trends
Institutional ownership remains a significant part of Getinge's shareholder base. Major holders include The Vanguard Group and BlackRock. The company's shareholder base is stable with a long-term perspective.
Recent Strategic Moves
Getinge acquired Paragonix Technologies, Inc. in Q3 2024. The company is phasing out the Surgical Perfusion product category. These moves aim to strengthen long-term growth.
Future Outlook
Getinge anticipates organic sales growth of 2-5% for 2025. These strategic decisions will likely shape the company's ownership structure. Investors will react to growth prospects and operational shifts.
Getinge Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Getinge Company?
- What is Competitive Landscape of Getinge Company?
- What is Growth Strategy and Future Prospects of Getinge Company?
- How Does Getinge Company Work?
- What is Sales and Marketing Strategy of Getinge Company?
- What is Brief History of Getinge Company?
- What is Customer Demographics and Target Market of Getinge Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.